linjc16/ctgov huggingface dataset:
Virtual Chromoendoscopy for Distal Polyps

Study Overview
=================
Brief Summary
-----------------
To assess the accuracy of predicting histology with virtual chromoendoscopy for distal colorectal polyps according to the ASGE PIVI statement.

Conditions
-----------------
Colorectal Polyps

Intervention / Treatment
-----------------
* Other: Prediction of histology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Screening or surveillance colonoscopy Exclusion Criteria: history of inflammatory bowel disease poor bowel preparation colectomy anticoagulation polyposis syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HD<br>Prediction of histology | Other: Prediction of histology<br> <br> |
| Virtual Chromoendoscopy<br>Prediction of histology | Other: Prediction of histology<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectivity of virtual chromoendoscopy | Upon visualization of a polyp in white-light, the location and size (as compared to open biopsy forceps or snare) are noted. Afterwards, virtual chromoendoscopy is used to visualize and enhance the mucosal vascular pattern and the mucosal surface pattern morphology of the polyp. The endoscopist makes a real time assessment of each polyp according to size, shape, Paris classification and surface characteristics including pit pattern and mucosal vascular pattern morphology, colour, and type of depression. Further, the endoscopist is assigning a level of confidence (high or low) to each real time prediction. Afterwards, all polyps are resected using standard techniques and processed for pathological evaluation. Each polyp is assessed by an experienced GI pathologist blinded to the real time prediction of polyp histology. Finally, real time and histological results are compared. | 3 years |
Topical Tranexamic Acid After Intravitreal Injections

Study Overview
=================
Brief Summary
-----------------
We aim to investigate whether topical administration of Tranexamic acid can reduce the occurence of subconjunctival hemorrahge after routine intravitreal injections for retinal conditions.

Official Title
-----------------
Topical Use of Tranexamic Acid for Prevention of Subconjunctival Hemorrhage After Intravitreal Injections

Conditions
-----------------
Subconjunctival Hemorrhage

Intervention / Treatment
-----------------
* Drug: Tranexamic acid
* Other: Balanced Salt Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects receiving intravitreal injections as part of their routine ophthalmological care Exclusion Criteria: Pregnancy, Oral contraceptives/HRT use, Known systemic autoimmune disease, Renal failure, active/suspected infection or inflammation in the treated eye, subconjunctival hemorrahge prior to inclusion, History of subarachnoid hemorrahge, thromboembolic events, increased risk for thromboembolic events, known sensitivity to the study drug

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Topical tranexamic acid<br> | Drug: Tranexamic acid<br>* A single drop administered topically<br>|
| Placebo Comparator: Topical BSS<br> | Other: Balanced Salt Solution<br>* A single drop administered topically<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subconjunctival hemorrahge |  | 3 days |
Normal Coronary Artery With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

Study Overview
=================
Brief Summary
-----------------
The investigators will investigate patients undergoing coronary angiography with normal coronary but slow blood flow that was normalized after adenosine injection into the coronary artery. The investigators believe that they have small vessel coronary disease which is the initial presentation of coronary disease prior to anatomical narrowing. To alleviate this phenomenon the investigators intend to examine the long-term clinical response of these patients to treatment with dipyridamole, a well-known medication with almost no side-effects that increases the level of adenosine in the tissue.

Official Title
-----------------
Normal Coronary Artery With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up

Conditions
-----------------
Coronary Angiography

Intervention / Treatment
-----------------
* Drug: Statin, aspirin
* Drug: Dipyridamole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing coronary angiography and who have normal coronary artery with slow blood flow that normalized with adenosine injection into the coronary artery Exclusion Criteria: Significant coronary disease Unstable patients Patients with known sensitivity to dipyridamole

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1. Routine treatment<br>Control group | Drug: Statin, aspirin<br> <br> |
| Experimental: 2. Dipyridamole treatment<br>Group that receives Dipyridamole treatment | Drug: Dipyridamole<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alleviation of chest pain |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Normal coronary artery with slow blood flow
Smoking and Alcohol Initiation

Study Overview
=================
Brief Summary
-----------------
This study evaluates multi-attribute utility, a modification of subjective expected utility, as a descriptive model of the adolescent's decision to initiate smoking or alcohol use. According to the model, the young decision maker envisions a set of consequences that will follow the two decision options, either to continue as a non-user or to initiate usage. Each consequence has three components. The components are the worth of the consequence, which may be positive or negative, the judged likelihood that the consequence will happen, and the importance of the consequence. Within an individual, importances will change with mood or circumstance, which is how the model accounts for impulsive decisions that may occur in social settings. The model will be tested by eliciting components of ten independent consequences from a large group of students early in the seventh-grade year. Current usage will also be examined; extant data suggest that most students will be non-users at that time. It is known that a fair amount of initiation takes place during the seventh and eighth grade years. The hypothesis is that those non-users whose model scores are high will be more likely to initiate usage than those whose scores are low. The same students will be queried regarding usage eighteen months later to evaluate the hypothesis. It is now well known that differential knowledge regarding the harmful effects of drug use does not distinguish adolescent users from non-users. The model approach quantifies the idea that anticipated positive consequences play a prominent role in the decision of those who choose to initiate. An important implication is that prevention campaigns might profit by addressing positive as well as negative consequences of usage.

Detailed Description
-----------------
A book entitled A science of decision making: the legacy of Ward Edwards and 4 chapters were published (Oxford University Press, 2008) with the support of this funding.

Official Title
-----------------
Predicting Tobacco and Alcohol Initiation

Conditions
-----------------
Smoking, Alcohol Drinking

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: enrolled middle school students Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 11 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Investigation of Blood Glucose and Insulin Response After Intake of Vitalose

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the postprandial glucose and insulin response of Vitalose.

Official Title
-----------------
Investigation of Blood Glucose and Insulin Response After Intake of Vitalose and Isomaltulose in Comparison to Sucrose and Glucose

Conditions
-----------------
Healthy Adults

Intervention / Treatment
-----------------
* Dietary Supplement: Vitalose
* Dietary Supplement: isomaltulose
* Dietary Supplement: sucrose
* Dietary Supplement: glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy adults Age 18-50 years BMI ≥18.5 and ≤30.0 kg/m² Exclusion Criteria: acute or chronic disease food allergy or intolerance intake of medications which affect glucose tolerance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vitalose<br>dissolved in water | Dietary Supplement: Vitalose<br>* dissolved in water<br>|
| Active Comparator: isomaltulose<br>dissolved in water | Dietary Supplement: isomaltulose<br>* dissolved in water<br>|
| Placebo Comparator: sucrose<br>dissolved in water | Dietary Supplement: sucrose<br>* dissolved in water<br>|
| Placebo Comparator: glucose<br>dissolved in water | Dietary Supplement: glucose<br>* dissolved in water<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 2h iAUC for pp glucose response |  | Baseline, 15, 30, 45, 60, 90, 120 minutes | 
| 2h iAUC for pp insulin response |  | Baseline, 15, 30, 45, 60, 90, 120 minutes |
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

Study Overview
=================
Brief Summary
-----------------
The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.

Conditions
-----------------
Dry Eye Syndromes

Intervention / Treatment
-----------------
* Drug: cyclosporine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of moderate to severe dry eye syndrome with or without Sjogren's syndrome or other autoimmune disease Exclusion Criteria: Intraocular or refractive surgery in the study eye within 3 months prior to study start Unwilling to discontinue use of contact lenses during the run-in and duration of the study Pregnancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: cyclosporine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Study on Clinical Features, Treatment Mode and Survival of Sarcoma

Study Overview
=================
Brief Summary
-----------------
The clinical data of all eligible patients who received chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgery in Henan Tumor Hospital from June 1, 2012 to May 30, 2022 were retrospectively collected.

Detailed Description
-----------------
This study was a single-center retrospective clinical study, which retrospectively collected the clinical data of all eligible patients receiving chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy and surgical treatment in Henan Tumor Hospital from June 1, 2012 to May 30, 2022. The efficacy, recurrence and survival of various treatments were collected.

Official Title
-----------------
A Single-center Retrospective Study of Clinical Features, Treatment Patterns, and Survival of Sarcomas

Conditions
-----------------
Sarcoma

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No age limit, male or female. A certain subtype of sarcoma was diagnosed by pathology in our hospital. Has received at least one hospitalization in this hospital. Target lesions can be evaluated according to solid tumor efficacy evaluation criteria (RECIST; Version 1.1) Measure diameter changes. Complete follow-up data. Exclusion Criteria: No clear pathology. Incomplete follow-up data.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival is defined as time from enrollment to the first occurrence of progression of disease or death from any cause within 63 days of last response assessment. | Up to approximately 24months | 
| Overall survival | Time from pathological diagnosis to death | Up to approximately 120months |
A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc

Study Overview
=================
Brief Summary
-----------------
Development of a novel computer software that will assist in measuring the cup/disc ratio in digital stereo optic disc images.

Official Title
-----------------
A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc

Conditions
-----------------
Developing Novel Technique of Measuring C/D Ratio From Digital Stereo Optic Disc Images, Intraobserver Reproducibility of C/D Measurements, Interobserver Variability of C/D Measurements

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who attended the Glaucoma service Patients with at least one pair of documented digital stereo optic disc images Satisfactory Quality of image allowing Cup Disc Ratio Evaluation Exclusion Criteria: Unsatisfactory Quality of image allowing Cup Disc Ratio Evaluation Novel software technique unable to process or analyze the image
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cup disc ratio measurement, digital stereo optic disc images
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drugs in the treatment of patients diagnosed with moderate to severe back pain treatment.

Detailed Description
-----------------
double-blind, double-dummy, non-inferiority, prospective, parallel group, intent to treat trial. Experiment duration: 04 days. 03 visits (days 0, 2 and 4). Efficacy will be evaluated for back pain relief based on visual analogic scale. Adverse events evaluation.

Official Title
-----------------
Randomized, Double Blind, Double Dummy To Non-Inferiority Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment

Conditions
-----------------
Back Pain

Intervention / Treatment
-----------------
* Drug: Ketorolac Tromethamine
* Drug: Naproxen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consent of the patient or legal guardian. Men or women aged between 18 and 65. Diagnosis of acute low back pain with moderate to severe pain (Visual Analogic score greater than 4 cm) Exclusion Criteria: fracture confirmed by X-ray Diagnosis of infection, fever, Pregnancy, lactation; Diagnosis of fibromyalgia; Hypersensitivity to ketorolac tromethamine, any of the ingredients of the formula or other Nonsteroidal anti-inflammatory

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Naproxen<br>2 tablets every 8 hours for 4 days. | Drug: Naproxen<br>* 2 tablets every 8 hours for 4 days<br>|
| Experimental: Ketorolac Tromethamine<br>10 drops every 8 hours for 4 days | Drug: Ketorolac Tromethamine<br>* 10 drops each 8 hours for 4 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS). | The individual response rate to the relieve of pain is calculated by measuring VAS during the first and last visit. The response rate is calculated using the following formula: Response rate = (VASvi - VASvf) / VASvi Considering: VASvi: VAS in the first visit; VASvf: VAS at the last visit; | 4 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety will be evaluated by the adverse events occurrences | Adverse events will be collected and followed in order to evaluate safety and tolerability | day 4 |
WHIRLPOOL FOR OSTEOARHRITIS

Study Overview
=================
Brief Summary
-----------------
Both neuropathic and nociceptive mechanisms may contribute to the OA pain experience. Aims: The aim of this study was to determine the efficacy of warm whirlpool on pain, disability, quality of life (QoL) and sleep for patients with neuropathic pain.

Detailed Description
-----------------
Whirlpool treatment method is used for medical and surgical conditions. In literature there are studies which recommend whirlpool therapy as a treatment for reducing pain in patients with osteoarthritis. The aim of this study was to determine the efficacy of warm whirlpool on pain, disability, quality of life (QoL) and sleep for patients with neuropathic pain.

Official Title
-----------------
THE EFFECTIVENESS OF WHIRLPOOL FOR PATIENTS WITH NEUROPATHIC PAIN DUE TO KNEE OSTEOARTHRITIS

Conditions
-----------------
Neuropathic Pain, Osteo Arthritis Knee, Sleep Disorder

Intervention / Treatment
-----------------
* Other: Whirlpool


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suffering from knee pain at least 3 months radiological manifestations considering were consistent with grade 3 and 4 knee OA due to Kellgren and Lawrence criteria had DN4 scores ≥4. Exclusion Criteria: lower extremity surgery history, knee infection inflammatory disease like rheumatoid arthritis back or pelvic pain related with knee pain another cause of polyneuropathy (diabetes mellitus, vitamin B 12 deficiency, toxic or neurological disease like stroke, spinal cord injury) lumbar disc herniation malignancy or active systemic disease.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intervention Group<br>Treated with warm whirlpool | Other: Whirlpool<br> <br> |
| Placebo Comparator: Placebo group<br>Treated with sham whirlpool | Other: Whirlpool<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual analogue scale |  | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short Form-36 Health Survey |  | one month | 
| Western Ontario and McMaster Universities Osteoarthritis Index |  | one month | 
| Pittsburgh Sleep Quality Index (PSQI) |  | one month | 
| DN4 |  | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuropathic Pain, Whirlpool, Osteoarthritis, Sleep